Analyst Desks Reshuffle Coverage: Healthcare Conviction Builds as Consumer Names Derate
Morgan Stanley initiates Achieve Life Sciences at overweight and PTC Therapeutics moves on a Fabry gene therapy acquisition, while EVgo and Highwoods Properties absorb rating downgrades
A heavy day of sell-side repositioning tilted toward biotech and specialty healthcare, with new overweight coverage and M&A-driven pipeline expansion, even as EV charging and office REIT exposures were marked down on execution and valuation grounds.